Galtec

We are a biotechnology company that transforms the scientific findings of the research group led by Dr Gabriel Rabinovich to develop new medicines based on galectin modulation for treating cancer, autoimmunity and chronic inflammatory diseases.

Our scientists have devoted nearly 30 years to researching galectins and their role in immune cell homeostasis. This research has yielded groundbreaking insights and given rise to a new paradigm known as Glyco-checkpoint. These innovative studies have been published in more than 300 scientific articles in leading journals, and our team has secured patent intellectual property.